

**Detection Rates, Pre-Test Carrier Risks, and Post-Test Residual Risks (Sorted by Gene)**

The detection rates and risks set forth below were derived using publicly available information, including gnomAD (<https://gnomad.broadinstitute.org>) and ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>), and the rates were extrapolated using appropriate scientific methodologies. Published studies were used to derive individual carrier risks for CYP21A2, HBA1/HBA2 and SMN1. As additional clinical evidence is available, the data in these charts may be updated from time to time. These data are provided for general informational purposes only and are not intended as a substitute for professional medical judgment or medical advice.

For unknown or mixed ethnicity, consider using the ethnic background with the most conservative risk estimates.

N/A= Not Available

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>DBT</b>	Maple syrup urine disease	African American/Black	99	1 in 380	1 in 38,000	1 in 150,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 342	1 in 34,000	1 in 140,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 429	1 in 43,000	1 in 170,000
<b>DCAF17</b>	Neurodegeneration with brain iron accumulation disorder	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>DCLRE1C</b>	Omenn syndrome	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>DDB2</b>	Xeroderma pigmentosum	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		<b>DDC</b>	Aromatic l-amino acid decarboxylase deficiency	African American/Black	99	< 1 in 500
Latino/Admixed American	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Ashkenazi Jewish	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
East Asian	99			1 in 134	1 in 13,000	1 in 52,000
Finnish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
South Asian	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Other (population not assigned)	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>DHCR7</b>	Smith-Lemli-Opitz syndrome	African American/Black	99	1 in 129	1 in 13,000	1 in 52,000
		Latino/Admixed American	99	1 in 136	1 in 14,000	1 in 56,000
		Ashkenazi Jewish	99	1 in 40	1 in 3,900	1 in 16,000
		East Asian	99	1 in 416	1 in 42,000	1 in 170,000
		Finnish	99	1 in 181	1 in 18,000	1 in 72,000
		Non-Finnish European/White	99	1 in 51	1 in 5,000	1 in 20,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 72	1 in 7,100	1 in 28,000
US general population	99	1 in 67	1 in 6,600	1 in 26,000		
<b>DHDDS</b>	Retinitis pigmentosa	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 97	1 in 9,600	1 in 38,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>DLAT</b>	Pyruvate dehydrogenase deficiency	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>DLD</b>	Dihydrolipoamide dehydrogenase deficiency	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 57	1 in 5,600	1 in 22,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>DMD</b>	Dystrophinopathies, including Duchenne and Becker muscular dystrophy and X-linked cardiomyopathy	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
US general population	99	N/A	N/A	N/A		
<b>DNMT3B</b>	Immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>DOCK8</b>	Severe combined immunodeficiency (SCID)	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 458	1 in 46,000	1 in 180,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>DOK7</b>	Congenital myasthenic syndrome	African American/Black	97	1 in 344	1 in 11,000	1 in 44,000
		Latino/Admixed American	97	1 in 424	1 in 14,000	1 in 56,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	97	1 in 281	1 in 9,300	1 in 37,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	97	1 in 324	1 in 11,000	1 in 44,000
<b>DPYD</b>	Dihydropyrimidine dehydrogenase deficiency	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 210	1 in 21,000	1 in 84,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	1 in 254	1 in 25,000	1 in 100,000
		South Asian	97	1 in 251	1 in 8,300	1 in 33,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 317	1 in 32,000	1 in 130,000
<b>DTNBP1</b>	Hermansky-Pudlak syndrome	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	1 in 489	1 in 16,000	1 in 64,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	1 in 450	1 in 22,000	1 in 88,000
		Other (population not assigned)	98	1 in 378	1 in 19,000	1 in 76,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>DYNC2H1</b>	Short-rib thoracic dysplasia	African American/Black	99	1 in 143	1 in 14,000	1 in 56,000
		Latino/Admixed American	99	1 in 183	1 in 18,000	1 in 72,000
		Ashkenazi Jewish	99	1 in 179	1 in 18,000	1 in 72,000
		East Asian	99	1 in 307	1 in 31,000	1 in 120,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 138	1 in 14,000	1 in 56,000
		South Asian	99	1 in 266	1 in 27,000	1 in 110,000
		Other (population not assigned)	99	1 in 164	1 in 16,000	1 in 64,000
		US general population	99	1 in 150	1 in 15,000	1 in 60,000
<b>DYSF</b>	Limb-girdle muscular dystrophy	African American/Black	99	1 in 143	1 in 14,000	1 in 56,000
		Latino/Admixed American	99	1 in 189	1 in 19,000	1 in 76,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 168	1 in 17,000	1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 263	1 in 26,000	1 in 100,000
		South Asian	99	1 in 298	1 in 30,000	1 in 120,000
		Other (population not assigned)	99	1 in 248	1 in 25,000	1 in 100,000
		US general population	99	1 in 220	1 in 22,000	1 in 88,000
<b>EDA</b>	Hypohidrotic ectodermal dysplasia	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	97	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
US general population	98	N/A	N/A	N/A		
<b>EFEMP2</b>	Cutis laxa	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
EIF2B1	Leukoencephalopathy with vanishing white matter	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
EIF2B2	Leukoencephalopathy with vanishing white matter	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
EIF2B3	Leukoencephalopathy with vanishing white matter	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
EIF2B4	Leukoencephalopathy with vanishing white matter	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>EIF2B5</b>	Leukoencephalopathy with vanishing white matter	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	1 in 485	1 in 48,000	1 in 190,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 457	1 in 46,000	1 in 180,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>ELP1</b>	Familial dysautonomia	African American/Black	99	1 in 434	1 in 43,000	1 in 170,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 37	1 in 3,600	1 in 14,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 343	1 in 34,000	1 in 140,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>EMD</b>	Emery-Dreifuss muscular dystrophy	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>ERCC2</b>	Xeroderma pigmentosum	African American/Black	99	1 in 347	1 in 35,000	1 in 140,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 107	1 in 11,000	1 in 44,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	1 in 202	1 in 20,000	1 in 80,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 312	1 in 31,000	1 in 120,000
		US general population	99	1 in 256	1 in 26,000	1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
ERCC3	Xeroderma pigmentosum	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 55	1 in 5,400	1 in 22,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	98	1 in 388	1 in 19,000	1 in 76,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	1 in 318	1 in 16,000	1 in 64,000
		US general population	98	1 in 455	1 in 23,000	1 in 92,000
ERCC4	Xeroderma pigmentosum	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	1 in 441	1 in 22,000	1 in 88,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
ERCC5	Xeroderma pigmentosum	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	1 in 283	1 in 28,000	1 in 110,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
ERCC6	Cockayne syndrome	African American/Black	98	1 in 314	1 in 16,000	1 in 64,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 420	1 in 42,000	1 in 170,000
		Finnish	99	1 in 265	1 in 26,000	1 in 100,000
		Non-Finnish European/White	99	1 in 331	1 in 33,000	1 in 130,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 378	1 in 38,000	1 in 150,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>ERCC8</b>	Cockayne syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 240	1 in 24,000	1 in 96,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>ESCO2</b>	Roberts syndrome	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>ETFA</b>	Glutaric acidemia type II	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>ETFB</b>	Glutaric acidemia type II	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>ETFDH</b>	Glutaric acidemia type II	African American/Black	99	1 in 361	1 in 36,000	1 in 140,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 133	1 in 13,000	1 in 52,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 411	1 in 41,000	1 in 160,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 421	1 in 42,000	1 in 170,000
<b>ETHE1</b>	Ethylmalonic encephalopathy	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>EVC2</b>	Ellis-van Creveld syndrome	African American/Black	99	1 in 267	1 in 27,000	1 in 110,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 297	1 in 30,000	1 in 120,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	1 in 318	1 in 11,000	1 in 44,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 422	1 in 42,000	1 in 170,000
		US general population	99	1 in 471	1 in 47,000	1 in 190,000
<b>EXOSC3</b>	Pontocerebellar hypoplasia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	1 in 496	1 in 50,000	1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 406	1 in 41,000	1 in 160,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 457	1 in 46,000	1 in 180,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>EYS</b>	Retinitis pigmentosa	African American/Black	97	1 in 71	1 in 2,300	1 in 9,200
		Latino/Admixed American	99	1 in 146	1 in 15,000	1 in 60,000
		Ashkenazi Jewish	99	1 in 42	1 in 4,100	1 in 16,000
		East Asian	99	1 in 62	1 in 6,100	1 in 24,000
		Finnish	98	1 in 39	1 in 1,900	1 in 7,600
		Non-Finnish European/White	99	1 in 106	1 in 11,000	1 in 44,000
		South Asian	98	1 in 220	1 in 11,000	1 in 44,000
		Other (population not assigned)	98	1 in 85	1 in 4,200	1 in 17,000
		US general population	98	1 in 103	1 in 5,100	1 in 20,000
<b>F9</b>	Factor IX deficiency (hemophilia B)	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
US general population	99	N/A	N/A	N/A		
<b>FA2H</b>	Neurodegeneration with brain iron accumulation disorder	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000		
<b>FAH</b>	Tyrosinemia type I	African American/Black	99	1 in 477	1 in 48,000	1 in 190,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 137	1 in 14,000	1 in 56,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 327	1 in 33,000	1 in 130,000
		Non-Finnish European/White	99	1 in 309	1 in 31,000	1 in 120,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 292	1 in 29,000	1 in 120,000
US general population	99	1 in 378	1 in 38,000	1 in 150,000		

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>FAM161A</b>	Retinitis pigmentosa	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	1 in 236	1 in 7,800	1 in 31,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	1 in 469	1 in 16,000	1 in 64,000
		Non-Finnish European/White	98	1 in 356	1 in 18,000	1 in 72,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	1 in 469	1 in 23,000	1 in 92,000
		<b>FANCA</b>	Fanconi anemia	African American/Black	99	1 in 185
Latino/Admixed American	99			1 in 319	1 in 32,000	1 in 130,000
Ashkenazi Jewish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
East Asian	98			1 in 246	1 in 12,000	1 in 48,000
Finnish	99			1 in 308	1 in 31,000	1 in 120,000
Non-Finnish European/White	99			1 in 174	1 in 17,000	1 in 68,000
South Asian	99			1 in 306	1 in 31,000	1 in 120,000
Other (population not assigned)	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	99			1 in 198	1 in 20,000	1 in 80,000
<b>FANCB</b>	Fanconi anemia	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
US general population	99	N/A	N/A	N/A		
<b>FANCC</b>	Fanconi anemia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 80	1 in 7,900	1 in 32,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	98	1 in 470	1 in 23,000	1 in 92,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>FANCD2</b>	Fanconi anemia	African American/Black	99	1 in 235	1 in 23,000	1 in 92,000
		Latino/Admixed American	99	1 in 385	1 in 38,000	1 in 150,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 399	1 in 40,000	1 in 160,000
		US general population	99	1 in 441	1 in 44,000	1 in 180,000
<b>FANCE</b>	Fanconi anemia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 469	1 in 47,000	1 in 190,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>FANCF</b>	Fanconi anemia	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
<b>FANCG</b>	Fanconi anemia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>FANCI</b>	Fanconi anemia	African American/Black	98	1 in 358	1 in 18,000	1 in 72,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	1 in 116	1 in 5,800	1 in 23,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	1 in 382	1 in 19,000	1 in 76,000
		Other (population not assigned)	98	1 in 468	1 in 23,000	1 in 92,000
		US general population	98	1 in 479	1 in 24,000	1 in 96,000
<b>FANCL</b>	Fanconi anemia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	1 in 391	1 in 20,000	1 in 80,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	1 in 479	1 in 24,000	1 in 96,000
<b>FBXL4</b>	Leigh syndrome	African American/Black	99	1 in 337	1 in 34,000	1 in 140,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 222	1 in 22,000	1 in 88,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 250	1 in 25,000	1 in 100,000
		US general population	99	1 in 283	1 in 28,000	1 in 110,000
<b>FHL1</b>	Emery-Dreifuss muscular dystrophy	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>FKBP10</b>	Osteogenesis imperfecta, autosomal recessive	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>FKRP</b>	Limb-girdle muscular dystrophy	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	1 in 413	1 in 41,000	1 in 160,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 266	1 in 27,000	1 in 110,000
		Finnish	99	1 in 272	1 in 27,000	1 in 110,000
		Non-Finnish European/White	99	1 in 190	1 in 19,000	1 in 76,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 246	1 in 25,000	1 in 100,000
US general population	99	1 in 247	1 in 25,000	1 in 100,000		
<b>FKTN</b>	Walker-Warburg syndrome and other FKTN related dystrophies	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	1 in 385	1 in 13,000	1 in 52,000
		Ashkenazi Jewish	97	1 in 63	1 in 2,100	1 in 8,400
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000		
<b>FMO3</b>	Trimethylaminuria	African American/Black	98	1 in 183	1 in 9,100	1 in 36,000
		Latino/Admixed American	99	1 in 374	1 in 37,000	1 in 150,000
		Ashkenazi Jewish	99	1 in 345	1 in 34,000	1 in 140,000
		East Asian	98	1 in 115	1 in 5,700	1 in 23,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	1 in 134	1 in 13,000	1 in 52,000
		South Asian	98	1 in 326	1 in 16,000	1 in 64,000
		Other (population not assigned)	99	1 in 130	1 in 13,000	1 in 52,000
US general population	99	1 in 158	1 in 16,000	1 in 64,000		

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>FOXN1</b>	Severe combined immunodeficiency (SCID)	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>FOXP3</b>	IPEX syndrome	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>FOXRED1</b>	Leigh syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	1 in 383	1 in 19,000	1 in 76,000
		South Asian	99	1 in 414	1 in 41,000	1 in 160,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	1 in 451	1 in 22,000	1 in 88,000
<b>FRAS1</b>	Fraser syndrome	African American/Black	98	1 in 390	1 in 19,000	1 in 76,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 491	1 in 49,000	1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>FREM2</b>	Fraser syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	1 in 393	1 in 20,000	1 in 80,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	1 in 490	1 in 24,000	1 in 96,000
<b>FUCA1</b>	Fucosidosis	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>G6PC1</b>	Glycogen storage disease type I	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	1 in 364	1 in 18,000	1 in 72,000
		Ashkenazi Jewish	99	1 in 77	1 in 7,600	1 in 30,000
		East Asian	99	1 in 186	1 in 19,000	1 in 76,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 342	1 in 34,000	1 in 140,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 375	1 in 37,000	1 in 150,000
<b>G6PD</b>	Glucose-6-phosphate dehydrogenase deficiency	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GAA</b>	Pompe disease	African American/Black	99	1 in 83	1 in 8,200	1 in 33,000
		Latino/Admixed American	99	1 in 119	1 in 12,000	1 in 48,000
		Ashkenazi Jewish	99	1 in 77	1 in 7,600	1 in 30,000
		East Asian	99	1 in 66	1 in 6,500	1 in 26,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 59	1 in 5,800	1 in 23,000
		South Asian	99	1 in 147	1 in 15,000	1 in 60,000
		Other (population not assigned)	99	1 in 77	1 in 7,600	1 in 30,000
		US general population	99	1 in 69	1 in 6,800	1 in 27,000
		<b>GALC</b>	Krabbe disease	African American/Black	98	< 1 in 500
Latino/Admixed American	99			1 in 371	1 in 37,000	1 in 150,000
Ashkenazi Jewish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
East Asian	99			1 in 49	1 in 4,800	1 in 19,000
Finnish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	99			1 in 254	1 in 25,000	1 in 100,000
South Asian	99			1 in 43	1 in 4,200	1 in 17,000
Other (population not assigned)	99			1 in 245	1 in 24,000	1 in 96,000
US general population	99			1 in 231	1 in 23,000	1 in 92,000
<b>GALE</b>	Galactosemia	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 415	1 in 41,000	1 in 160,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GALK1</b>	Galactosemia	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	1 in 446	1 in 45,000	1 in 180,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GALNS</b>	Mucopolysaccharidosis type IVA	African American/Black	99	1 in 441	1 in 44,000	1 in 180,000
		Latino/Admixed American	99	1 in 317	1 in 32,000	1 in 130,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 488	1 in 49,000	1 in 200,000
		Finnish	98	1 in 469	1 in 23,000	1 in 92,000
		Non-Finnish European/White	99	1 in 428	1 in 43,000	1 in 170,000
		South Asian	99	1 in 433	1 in 43,000	1 in 170,000
		Other (population not assigned)	99	1 in 307	1 in 31,000	1 in 120,000
		US general population	99	1 in 401	1 in 40,000	1 in 160,000
		<b>GALT</b>	Galactosemia, classic	African American/Black	98	1 in 98
Latino/Admixed American	97			1 in 222	1 in 22,000	1 in 88,000
Ashkenazi Jewish	97			< 1 in 500	< 1 in 50,000	< 1 in 200,000
East Asian	97			1 in 421	1 in 42,000	1 in 170,000
Finnish	97			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	97			1 in 131	1 in 13,000	1 in 52,000
South Asian	99			1 in 383	1 in 38,000	1 in 150,000
Other (population not assigned)	97			1 in 264	1 in 26,000	1 in 100,000
US general population	97			1 in 143	1 in 14,000	1 in 56,000
<b>GAMT</b>	Cerebral creatine deficiency syndromes	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GATM</b>	Cerebral creatine deficiency syndromes	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GBA1</b>	Gaucher disease	African American/Black	87	1 in 172	1 in 1,300	1 in 5,200
		Latino/Admixed American	87	1 in 152	1 in 1,200	1 in 4,800
		Ashkenazi Jewish	87	1 in 15	1 in 110	1 in 440
		East Asian	87	1 in 235	1 in 1,800	1 in 7,200
		Finnish	87	1 in 132	1 in 1,000	1 in 4,000
		Non-Finnish European/White	87	1 in 109	1 in 830	1 in 3,300
		South Asian	87	1 in 279	1 in 2,100	1 in 8,400
		Other (population not assigned)	87	1 in 91	1 in 690	1 in 2,800
		US general population	87	1 in 124	1 in 950	1 in 3,800
<b>GBE1</b>	Glycogen storage disease type IV	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	1 in 303	1 in 15,000	1 in 60,000
		Ashkenazi Jewish	99	1 in 72	1 in 7,100	1 in 28,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 374	1 in 37,000	1 in 150,000
		Non-Finnish European/White	99	1 in 242	1 in 24,000	1 in 96,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 149	1 in 15,000	1 in 60,000
		US general population	99	1 in 279	1 in 28,000	1 in 110,000
<b>GCDH</b>	Glutaric acidemia type I	African American/Black	99	1 in 213	1 in 21,000	1 in 84,000
		Latino/Admixed American	99	1 in 251	1 in 25,000	1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 217	1 in 22,000	1 in 88,000
		Finnish	99	1 in 356	1 in 36,000	1 in 140,000
		Non-Finnish European/White	99	1 in 204	1 in 20,000	1 in 80,000
		South Asian	99	1 in 289	1 in 29,000	1 in 120,000
		Other (population not assigned)	99	1 in 283	1 in 28,000	1 in 110,000
		US general population	99	1 in 215	1 in 21,000	1 in 84,000
<b>GFM1</b>	Combined oxidative phosphorylation deficiency	African American/Black	98	1 in 459	1 in 23,000	1 in 92,000
		Latino/Admixed American	99	1 in 485	1 in 48,000	1 in 190,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	1 in 432	1 in 22,000	1 in 88,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	1 in 456	1 in 46,000	1 in 180,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GFPT1</b>	Congenital myasthenic syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GJB2</b>	Deafness and hearing loss, nonsyndromic	African American/Black	99	1 in 63	1 in 6,200	1 in 25,000
		Latino/Admixed American	95	1 in 23	1 in 440	1 in 1,800
		Ashkenazi Jewish	98	1 in 12	1 in 550	1 in 2,200
		East Asian	99	1 in 6	1 in 500	1 in 2,000
		Finnish	99	1 in 16	1 in 1,500	1 in 6,000
		Non-Finnish European/White	99	1 in 18	1 in 1,700	1 in 6,800
		South Asian	99	1 in 58	1 in 5,700	1 in 23,000
		Other (population not assigned)	99	1 in 20	1 in 1,900	1 in 7,600
		US general population	99	1 in 19	1 in 1,800	1 in 7,200
<b>GLA</b>	Fabry disease	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>GLB1</b>	GM1 gangliosidosis and mucopolysaccharidosis type IVB	African American/Black	99	1 in 334	1 in 33,000	1 in 130,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	1 in 397	1 in 20,000	1 in 80,000
		Finnish	98	1 in 258	1 in 13,000	1 in 52,000
		Non-Finnish European/White	99	1 in 326	1 in 33,000	1 in 130,000
		South Asian	99	1 in 318	1 in 32,000	1 in 130,000
		Other (population not assigned)	99	1 in 337	1 in 34,000	1 in 140,000
		US general population	99	1 in 352	1 in 35,000	1 in 140,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GLDC</b>	Glycine encephalopathy	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 247	1 in 25,000	1 in 100,000
		Non-Finnish European/White	99	1 in 311	1 in 31,000	1 in 120,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 372	1 in 37,000	1 in 150,000
		US general population	99	1 in 375	1 in 37,000	1 in 150,000
<b>GLE1</b>	Congenital arthrogryposis with anterior horn cell disease	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 42	1 in 4,100	1 in 16,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 442	1 in 44,000	1 in 180,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GNE</b>	Inclusion body myopathy 2	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 122	1 in 12,000	1 in 48,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 374	1 in 37,000	1 in 150,000
		South Asian	99	1 in 37	1 in 3,600	1 in 14,000
		Other (population not assigned)	99	1 in 220	1 in 22,000	1 in 88,000
		US general population	99	1 in 345	1 in 34,000	1 in 140,000
<b>GNPAT</b>	Rhizomelic chondrodysplasia punctata	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GNPTAB</b>	Mucopolipidosis type II and III	African American/Black	97	1 in 180	1 in 6,000	1 in 24,000
		Latino/Admixed American	97	1 in 306	1 in 10,000	1 in 40,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 391	1 in 39,000	1 in 160,000
		Finnish	97	1 in 165	1 in 5,500	1 in 22,000
		Non-Finnish European/White	98	1 in 258	1 in 13,000	1 in 52,000
		South Asian	98	1 in 319	1 in 16,000	1 in 64,000
		Other (population not assigned)	97	1 in 295	1 in 9,800	1 in 39,000
		US general population	98	1 in 256	1 in 13,000	1 in 52,000
		<b>GNPTG</b>	Mucopolipidosis III gamma	African American/Black	97	1 in 394
Latino/Admixed American	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
Ashkenazi Jewish	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
East Asian	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
Finnish	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
Non-Finnish European/White	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
South Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Other (population not assigned)	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
US general population	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
<b>GNS</b>	Mucopolysaccharidosis type III	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GPHN</b>	Molybdenum cofactor deficiency	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>GRHPR</b>	Primary hyperoxaluria	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	97	1 in 469	1 in 16,000	1 in 64,000
		South Asian	99	1 in 333	1 in 33,000	1 in 130,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>GRIP1</b>	Fraser syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GSS</b>	Glutathione synthetase deficiency	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>GUSB</b>	Mucopolysaccharidosis type VII	African American/Black	99	1 in 427	1 in 43,000	1 in 170,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HADHA</b>	Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency	African American/Black	99	1 in 444	1 in 44,000	1 in 180,000
		Latino/Admixed American	99	1 in 392	1 in 39,000	1 in 160,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	1 in 127	1 in 13,000	1 in 52,000
		Non-Finnish European/White	99	1 in 216	1 in 22,000	1 in 88,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 249	1 in 25,000	1 in 100,000
		US general population	99	1 in 267	1 in 27,000	1 in 110,000
<b>HADHB</b>	Mitochondrial trifunctional protein deficiency	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HAMP</b>	Juvenile hereditary hemochromatosis	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HAX1</b>	Severe congenital neutropenia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HBA1/HBA2</b>	Alpha-thalassemia	African	90	1 in 3	N/A	N/A
		American	90	1 in 21	N/A	N/A
		Eastern Mediterranean	90	1 in 5	N/A	N/A
		European	90	1 in 44	N/A	N/A
		Southeast Asian	90	1 in 2	N/A	N/A
		Western Pacific	90	1 in 10	N/A	N/A
<b>HBB</b>	Beta-hemoglobinopathies, includes sickle cell disease and beta-thalassemias	African American/Black	99	1 in 9	1 in 800	1 in 3,200
		Latino/Admixed American	99	1 in 162	1 in 16,000	1 in 64,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	1 in 107	1 in 5,300	1 in 21,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	1 in 256	1 in 26,000	1 in 100,000
		South Asian	99	1 in 28	1 in 2,700	1 in 11,000
		Other (population not assigned)	99	1 in 116	1 in 12,000	1 in 48,000
US general population	99	1 in 52	1 in 5,100	1 in 20,000		
<b>HCFC1</b>	Methylmalonic acidemia with homocystinuria	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	97	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
US general population	97	N/A	N/A	N/A		
<b>HELLS</b>	Immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000		

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HEXA</b>	Tay-Sachs disease	African American/Black	99	1 in 317	1 in 32,000	1 in 130,000
		Latino/Admixed American	99	1 in 288	1 in 29,000	1 in 120,000
		Ashkenazi Jewish	97	1 in 31	1 in 1,000	1 in 4,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	1 in 265	1 in 26,000	1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	1 in 252	1 in 8,400	1 in 34,000
		US general population	99	1 in 285	1 in 28,000	1 in 110,000
		<b>HEXB</b>	Sandhoff disease	African American/Black	99	< 1 in 500
Latino/Admixed American	98			1 in 325	1 in 16,000	1 in 64,000
Ashkenazi Jewish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
East Asian	99			1 in 472	1 in 47,000	1 in 190,000
Finnish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	99			1 in 278	1 in 28,000	1 in 110,000
South Asian	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Other (population not assigned)	98			1 in 467	1 in 23,000	1 in 92,000
US general population	99			1 in 325	1 in 32,000	1 in 130,000
<b>HGSNAT</b>	Mucopolysaccharidosis type III	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	1 in 482	1 in 48,000	1 in 190,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 485	1 in 48,000	1 in 190,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HINT1</b>	Axonal neuropathy with neuromyotonia	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HJV</b>	Juvenile hereditary hemochromatosis	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		<b>H LCS</b>	Holocarboxylase synthetase deficiency	African American/Black	97	< 1 in 500
Latino/Admixed American	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Ashkenazi Jewish	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
East Asian	99			1 in 361	1 in 36,000	1 in 140,000
Finnish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
South Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Other (population not assigned)	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
US general population	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HMGCL</b>	HMG-CoA lyase deficiency			African American/Black	98	< 1 in 500
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HOGA1</b>	Primary hyperoxaluria	African American/Black	99	1 in 425	1 in 42,000	1 in 170,000
		Latino/Admixed American	99	1 in 285	1 in 28,000	1 in 110,000
		Ashkenazi Jewish	97	1 in 48	1 in 1,600	1 in 6,400
		East Asian	99	1 in 113	1 in 11,000	1 in 44,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 183	1 in 18,000	1 in 72,000
		South Asian	99	1 in 420	1 in 42,000	1 in 170,000
		Other (population not assigned)	99	1 in 136	1 in 14,000	1 in 56,000
		US general population	99	1 in 207	1 in 21,000	1 in 84,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HPD</b>	Tyrosinemia type III	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		<b>HPS1</b>	Hermansky-Pudlak syndrome	African American/Black	98	< 1 in 500
Latino/Admixed American	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Ashkenazi Jewish	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
East Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Finnish	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
Non-Finnish European/White	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
South Asian	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Other (population not assigned)	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
US general population	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>HPS3</b>	Hermansky-Pudlak syndrome			African American/Black	97	< 1 in 500
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 287	1 in 29,000	1 in 120,000
		East Asian	99	1 in 290	1 in 29,000	1 in 120,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	1 in 489	1 in 24,000	1 in 96,000
		South Asian	99	1 in 371	1 in 37,000	1 in 150,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>HPS4</b>	Hermansky-Pudlak syndrome	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HPS5</b>	Hermansky-Pudlak syndrome	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	1 in 252	1 in 8,400	1 in 34,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		<b>HPS6</b>	Hermansky-Pudlak syndrome	African American/Black	98	< 1 in 500
Latino/Admixed American	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
Ashkenazi Jewish	97			< 1 in 500	< 1 in 17,000	< 1 in 68,000
East Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Finnish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
South Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Other (population not assigned)	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>HSD3B2</b>	Congenital adrenal hyperplasia	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HSD17B10</b>	HSD10 disease	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>HSD17B4</b>	D-bifunctional protein deficiency	African American/Black	98	1 in 473	1 in 24,000	1 in 96,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		<b>HYAL1</b>	Mucopolysaccharidosis type IX	African American/Black	97	< 1 in 500
Latino/Admixed American	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Ashkenazi Jewish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
East Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Finnish	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
Non-Finnish European/White	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
South Asian	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
Other (population not assigned)	99			< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	98			< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>HYCC1</b>	Hypomyelination and congenital cataract	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>HYLS1</b>	Hydrolethalus syndrome	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>IDS</b>	Mucopolysaccharidosis type II	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	97	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	97	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	97	N/A	N/A	N/A
<b>IDUA</b>	Mucopolysaccharidosis type I	African American/Black	99	1 in 447	1 in 45,000	1 in 180,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	1 in 421	1 in 42,000	1 in 170,000
		Finnish	99	1 in 178	1 in 18,000	1 in 72,000
		Non-Finnish European/White	99	1 in 98	1 in 9,700	1 in 39,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 354	1 in 35,000	1 in 140,000
		US general population	99	1 in 142	1 in 14,000	1 in 56,000
<b>IFT140</b>	Retinitis pigmentosa	African American/Black	98	1 in 348	1 in 17,000	1 in 68,000
		Latino/Admixed American	98	1 in 498	1 in 25,000	1 in 100,000
		Ashkenazi Jewish	99	1 in 171	1 in 17,000	1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	1 in 307	1 in 31,000	1 in 120,000
		South Asian	99	1 in 450	1 in 45,000	1 in 180,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 351	1 in 35,000	1 in 140,000
<b>IKBKB</b>	Severe combined immunodeficiency (SCID)	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>IL2RA</b>	Severe combined immunodeficiency (SCID)	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>IL2RG</b>	Severe combined Immunodeficiency (SCID), X-linked	African American/Black	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/White	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
US general population	99	N/A	N/A	N/A		
<b>IL7R</b>	Severe combined immunodeficiency (SCID)	African American/Black	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000		
<b>INPP5E</b>	Joubert syndrome and related disorders, including Meckel-Gruber syndrome	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000		

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>ITPA</b>	Developmental and epileptic encephalopathy	African American/Black	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>IVD</b>	Isovaleric acidemia	African American/Black	99	1 in 354	1 in 35,000	1 in 140,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/White	99	1 in 273	1 in 27,000	1 in 110,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 349	1 in 35,000	1 in 140,000
		US general population	99	1 in 325	1 in 32,000	1 in 130,000
<b>JAK3</b>	Severe combined immunodeficiency (SCID)	African American/Black	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/White	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000		